CD4 and myeloid sarcoma: In natalizumab-treated MS patients, VLA-4 expression was significantly decreased on CD197+CD4+ T-cells and CD27+CD197− CD4+ T-cells but not on CD27− CCR7− CD4+ T-cells (Figure 2C).